Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-14 · accession 0000905148-24-000760 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-16 | 2024-02-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $3.40 | -41.9K | 2.62M | -2% | -$142.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-14 | F | D | 41,861 | $3.40 | 2,616,812 | D | — | — |